中国医学前沿杂志（电子版）2024，Vol.16Issue(7)：97-103,7.DOI:10.12037/YXQY.2024.07-13
托珠单抗在结缔组织病相关间质性肺病治疗中的进展及展望
Progress and prospects of tocilizumab in treatment of connective tissue disease-associated interstitial lung disease
摘要
Abstract
Connective tissue diseases(CTDs)are a group of autoimmune diseases that influence multiple organs and systems,with the lung being a commonly affected site.Interstitial lung disease(ILD)is one of the main clinical manifestations of CTD and is characterized by inflammation or fibrosis of the lung interstitium,leading to impaired lung function,respiratory difficulties,and reduced quality of life.Interleukin-6(IL-6)promotes inflammatory responses,stimulates fibroblast proliferation and collagen synthesis,and plays a crucial role in the pathogenesis of connective tissue disease-associated interstitial lung disease(CTD-ILD).Tocilizumab,an IL-6 receptor antagonist,has been widely used in the treatment of CTDs such as rheumatoid arthritis in recent years,and has also shown promising efficacy in the treatment of CTD-ILD.This article reviews the progress of Tocilizumab in the treatment of CTD-ILD,aiming to provide a theoretical basis for the treatment strategies of CTD-ILD.关键词
结缔组织病/间质性肺病/托珠单抗Key words
Connective tissue disease/Interstitial lung disease/Tocilizumab引用本文复制引用
李芝谕,陈哲,王钱,李可天,程永静..托珠单抗在结缔组织病相关间质性肺病治疗中的进展及展望[J].中国医学前沿杂志（电子版）,2024,16(7):97-103,7.基金项目
National High Level Hospital Clinical Research Funding(BJ-2021-235) （BJ-2021-235）
National High Level Hospital Clinical Research Funding(BJ-2021-192) 中央高水平医院临床科研业务费(BJ-2021-235) （BJ-2021-192）
中央高水平医院临床科研业务费(BJ-2021-192) （BJ-2021-192）
